- A 54.6% year-over-year increase in Dupixent (dupilimumab) sales to ~€1.4B (~$1.6B) helped Sanofi (NASDAQ:SNY) beat Q3 2021 earnings expectations.
- That helped specialty care sales increase 20.2% to ~€3.3B (~$3.8B). Speciality care accounted for 31.5% of overall sales.
- Another bright spot in Q3 were vaccine sales which soared 16.5% to ~€2.4B (~$2.8B). That accounted for 23.2% of overall sales.
- Influenza vaccine sales increased 25.5% to ~€1.3B (~$1.6B) due in large part to earlier shipments to the U.S.
- The oncology franchise also showed growth of 8.1% YoY. Sarclisa (isatuximab-irfc) sales grew 276.9% to €48M (~$55.7M) driven by additional launches in Europe and higher sales in the U.S. and the rest of the world.
- General medicines, Sanofi's largest business segment, saw a 1.7% sales decrease to €3.6B ($4.1B). The company attributed the decline to a decrease in sales of Lantus (insulin glargine) and Aprovel/Avapro (irbesartan) in the U.S.
- Sanofi also upped its full-year guidance and now expects 2021 business EPS to grow around 14%.
- Earlier this week, BofA said that a potential indication for Dupixent in eosinophilic esophagitis could add more than €1B in sales.